Genetic mutation test kit HWTS-GE012A

whole bloodfluorescencefor RT-PCR

This kit is used for in vitro qualitative detection of the polymorphism of CYP2C19 genes CYP2C19*2 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*17 (rs12248560, c.806>T) in genomic DNA of human whole blood samples. CYP2C19 is one of the important drug metabolizing enzymes in the CYP450 family. Many endogenous substrates and about 2% of clinical drugs are metabolized by CYP2C19, such as the metabolism of antiplatelet aggregation inhibitors (like clopidogrel), proton pump inhibitors (omeprazole), anticonvulsants, etc [1-2]. CYP2C19 gene polymorphisms also have differences in the metabolizing ability of related drugs. These point mutations of *2 (rs4244285) and *3 (rs4986893) cause the loss of the enzyme activity encoded by the CYP2C19 gene and the weakness of metabolic substrate ability, and increase the blood concentration, so as to cause adverse drug reactions related to blood concentration. *17 (rs12248560) could increase the enzyme activity encoded by CYP2C19 gene, the production of active metabolites, and enhance the platelet aggregation inhibition and increase the bleeding risk.